SILVER SPRING, Md., Oct. 05, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article is written by Dr. Ronald L. Korn, MD, Ph.D., who is the Founder, Chairman and Chief Medical Officer of Imaging Endpoints in Scottsdale, Arizona. Imaging Endpoints is the company that will perform the radiologic imaging that will be required for PharmaCyte Biotech’s upcoming Phase 2b clinical trial in pancreatic cancer. 

The article titled, “Imaging to Cure Cancer: Valuable Contribution of Radiology for Clinical Trial Success,” highlights the role Imaging Endpoints will play in PharmaCyte Biotech’s pivotal Phase 2b clinical trial. The article discusses: (i) the use of radiologic imaging to detect, track and confirm treatment responses in clinical trials; (ii) the unique aspects and opportunities for Cell-in-a-Box® to treat pancreatic cancer; and (iii) PharmaCyte Biotech’s upcoming Phase 2b clinical trial.

In the article, Dr. Korn explains, “PharmaCyte Biotech’s Cell-in-A-Box® technology provides a new approach to treat this deadly disease (pancreatic cancer) by potentially reducing the pancreatic tumor burden enough to offer patients a chance at a surgical cure. However, knowing whether treatment is working or not is one of the single most critical elements for delivering the right care to patients at the right time. Determining this, of course, is not a simple task. It requires both laboratory and radiology confirmation that a treatment is making a difference.”

PharmaCyte Biotech’s Chief Operating Officer, Dr. Gerald W. Crabtree, commented, “Dr. Korn’s comprehensive article is extremely informative. Among the many important factors discussed in the article, Dr. Korn emphasizes that the radiologic imaging must be consistent among all study sites and the subsequent analyses of all of the radiologic images must be centralized. The types of advanced radiologic analyses that Dr. Korn and his colleagues can provide will give us the most definitive radiologic data possible. From the in-depth nature of Dr. Korn’s article and the knowledge that his company has performed such advanced analyses for over 100 clinical trials in the U.S. and throughout the world, it is evident that PharmaCyte Biotech could not have chosen a better company than Imaging Endpoints for the radiology studies that will be part of our Phase 2b clinical trial.”

Read Dr. Korn’s exclusive article on Imaging to Cure Cancer and his company’s role in PharmaCyte’s Phase 2b clinical trial at:

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.

PharmaCyte Biotech’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856

Primary Logo

Source: PharmaCyte Biotech, Inc.